Loading...
XSHE
000403
Market cap1.97bUSD
Dec 05, Last price  
14.68CNY
1D
0.89%
1Q
-18.44%
Jan 2017
-12.62%
Name

Pacific Shuanglin Bio-pharmacy Co Ltd

Chart & Performance

D1W1MN
XSHE:000403 chart
P/E
18.72
P/S
5.26
EPS
0.78
Div Yield, %
1.36%
Shrs. gr., 5y
8.36%
Rev. gr., 5y
23.72%
Revenues
2.65b
+14.00%
742,951,367674,900,344645,031,389578,800,850465,910,788545,673,096461,068,440469,824,199477,715,809489,495,707500,269,283567,436,434685,378,117859,843,304915,656,5681,049,937,6911,971,734,3152,405,188,4252,328,723,2792,654,684,638
Net income
745m
+21.76%
0034,608,101202,007,7462,328,37629,226,74040,706,45932,573,52270,280,260122,516,59577,563,03753,895,94515,244,65279,982,796160,448,038185,965,308391,063,978587,131,491612,111,043745,320,757
CFO
322m
-52.61%
49,058,568095,029,80474,902,010111,864,9209,878,186130,137,466123,244,98591,006,89977,039,22170,310,54062,487,3610116,634,762190,843,307194,839,665408,218,063524,218,863679,006,331321,790,406
Dividend
Jun 28, 20240.19993 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.
IPO date
Jun 28, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT